In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

limited upside in pipeline catalysts and 2025 estimates “makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.50. The company’s shares closed yesterday ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...

GSK is investing up to $800 million to double the size and capacity of its production site in Marietta, Pennsylvania, the company said Thursday. Through the addition of two new facilities ...

IN MARIETTA, L Hundreds of millions of dollars and hundreds of new jobs are coming to Lancaster County.Vaccine manufacturer GSK announced Thursday it will invest $800 million to expand its ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

London-based GSK is crossing the pond to form a new lung disease research collaboration with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

Preliminary results from two trials showed that GSK’s respiratory syncytial virus ... the shot for a larger population. In one of the new Arexvy trials, a single dose triggered robust immune ...